13.67
Avalo Therapeutics Inc stock is traded at $13.67, with a volume of 273.87K.
It is down -2.01% in the last 24 hours and up +28.30% over the past month.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
See More
Previous Close:
$13.95
Open:
$13.79
24h Volume:
273.87K
Relative Volume:
0.86
Market Cap:
$179.79M
Revenue:
$1.93M
Net Income/Loss:
$-7.96M
P/E Ratio:
-0.00387
EPS:
-3530.8178
Net Cash Flow:
$-36.78M
1W Performance:
-2.36%
1M Performance:
+28.30%
6M Performance:
+178.98%
1Y Performance:
+43.29%
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
1500 LIBERTY RIDGE DRIVE, WAYNE
Compare AVTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
AVTX
Avalo Therapeutics Inc
|
13.67 | 248.31M | 1.93M | -7.96M | -36.78M | -3,530.82 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
Sep-05-25 | Initiated | TD Cowen | Buy |
Aug-15-25 | Initiated | Cantor Fitzgerald | Overweight |
Jun-02-25 | Resumed | H.C. Wainwright | Buy |
Mar-25-25 | Initiated | Jefferies | Buy |
Mar-25-25 | Initiated | Stifel | Buy |
Feb-28-25 | Initiated | Piper Sandler | Overweight |
Feb-21-25 | Initiated | Wedbush | Outperform |
Dec-19-24 | Initiated | BTIG Research | Buy |
Oct-24-24 | Initiated | H.C. Wainwright | Neutral |
Apr-16-24 | Upgrade | Oppenheimer | Perform → Outperform |
Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
View All
Avalo Therapeutics Inc Stock (AVTX) Latest News
Real time social sentiment graph for Avalo Therapeutics Inc.Portfolio Performance Report & Pattern Based Trade Signal System - newser.com
Will Avalo Therapeutics Inc. stock keep outperforming rivalsJuly 2025 Momentum & Community Supported Trade Ideas - newser.com
Will Avalo Therapeutics Inc. stock deliver long term returns2025 Valuation Update & Daily Chart Pattern Signal Reports - newser.com
How Avalo Therapeutics Inc. (C6K0) stock responds to job market shiftsProfit Target & Fast Moving Trade Plans - newser.com
Technical analysis overview for Avalo Therapeutics Inc. stockFed Meeting & Capital Efficient Trading Techniques - newser.com
Why Avalo Therapeutics Inc. stock remains on watchlists2025 Momentum Check & Daily Stock Momentum Reports - newser.com
Multi factor analysis applied to Avalo Therapeutics Inc.Weekly Trade Analysis & Risk Controlled Daily Trade Plans - newser.com
Is it time to cut losses on Avalo Therapeutics Inc.July 2025 Snapshot & Capital Efficient Trading Techniques - newser.com
Will Avalo Therapeutics Inc. stock benefit from upcoming earnings reportsEarnings Performance Report & Daily Oversold Stock Bounce Ideas - newser.com
Avalo Therapeutics Inc. stock trend forecastMarket Movement Recap & Consistent Profit Trade Alerts - newser.com
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
How high can Avalo Therapeutics Inc. stock goJuly 2025 Macro Moves & Entry and Exit Point Strategies - newser.com
Avalo Therapeutics, Inc. Updates Investor Presentation - TradingView
Should I buy Avalo Therapeutics Inc. (C6K0) stock before earnings season2025 Year in Review & Fast Entry and Exit Trade Plans - newser.com
How Avalo Therapeutics Inc. stock performs in weak economyRecession Risk & Smart Swing Trading Techniques - newser.com
Can Avalo Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Analyst Calls & High Accuracy Swing Entry Alerts - newser.com
Will Avalo Therapeutics Inc. see short term momentumWall Street Watch & Low Risk Growth Stock Ideas - newser.com
Is Avalo Therapeutics Inc. (C6K0) stock positioned for secular growthRate Hike & Breakout Confirmation Alerts - newser.com
How moving averages guide Avalo Therapeutics Inc. trading2025 Biggest Moves & AI Driven Stock Reports - newser.com
Can Avalo Therapeutics Inc. (C6K0) stock sustain revenue momentum2025 Technical Patterns & Reliable Price Action Trade Plans - newser.com
Is Avalo Therapeutics Inc a good long term investmentRisk Mitigation Techniques & Free Superior Profit Margins - earlytimes.in
Why Avalo Therapeutics Inc. (C6K0) stock remains top rated2025 Market Outlook & AI Forecasted Entry/Exit Points - newser.com
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Significant Increase in Short Interest - Defense World
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update - MarketBeat
Avalo Therapeutics Strengthens Leadership with Key Appointments - The Globe and Mail
Avalo Therapeutics Expands Leadership Team with Key - GlobeNewswire
Avalo Therapeutics, Inc. Announces Board Appointments, Effective October 1, 2025 - MarketScreener
Avalo Therapeutics expands leadership with two senior appointments By Investing.com - Investing.com Canada
Avalo Therapeutics expands leadership with two senior appointments - Investing.com India
Former Longboard $2.6B Deal Architect Joins Avalo Therapeutics as CBO Ahead of Key Trial Results - Stock Titan
BTIG Research Reiterates “Buy” Rating for Avalo Therapeutics (NASDAQ:AVTX) - Defense World
Avalo Therapeutics' (AVTX) Buy Rating Reiterated at BTIG Research - MarketBeat
BTIG Reiterates Avalo Therapeutics (AVTX) Buy Recommendation - Nasdaq
BTIG Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $40 - 富途牛牛
What drives Avalo Therapeutics Inc stock priceSector Performance Drivers & Free Dashboard to Track Market Momentum - earlytimes.in
What analysts say about Avalo Therapeutics Inc stockBlue Chip Stock Analysis & Superior Trading Ideas - earlytimes.in
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avalo Therapeutics Inc Stock (AVTX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Almenoff June Sherie | Director |
Nov 12 '24 |
Buy |
12.50 |
500 |
6,250 |
500 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):